JPWO2024111564A1 - - Google Patents
Info
- Publication number
- JPWO2024111564A1 JPWO2024111564A1 JP2024560151A JP2024560151A JPWO2024111564A1 JP WO2024111564 A1 JPWO2024111564 A1 JP WO2024111564A1 JP 2024560151 A JP2024560151 A JP 2024560151A JP 2024560151 A JP2024560151 A JP 2024560151A JP WO2024111564 A1 JPWO2024111564 A1 JP WO2024111564A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022185972 | 2022-11-21 | ||
| PCT/JP2023/041699 WO2024111564A1 (ja) | 2022-11-21 | 2023-11-21 | トポテカン又はその塩を内包するリポソーム組成物およびｄｎａ損傷修復阻害剤を含む組合せ医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2024111564A1 true JPWO2024111564A1 (https=) | 2024-05-30 |
Family
ID=91195598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560151A Pending JPWO2024111564A1 (https=) | 2022-11-21 | 2023-11-21 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250268827A1 (https=) |
| EP (1) | EP4623915A4 (https=) |
| JP (1) | JPWO2024111564A1 (https=) |
| CN (1) | CN120225196A (https=) |
| TW (1) | TW202434243A (https=) |
| WO (1) | WO2024111564A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090285878A1 (en) * | 2004-11-05 | 2009-11-19 | Tekmira Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
| JP7042739B2 (ja) * | 2015-08-20 | 2022-03-28 | イプセン バイオファーム リミティド | 癌処置のためのリポソーム型イリノテカン及びｐａｒｐ阻害薬を使用する併用療法 |
| EP4647126A3 (en) * | 2015-10-16 | 2026-02-11 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
| EP3423048A4 (en) * | 2016-02-29 | 2019-10-23 | Synta Pharmaceuticals Corp. | COMBINATION THERAPY FOR THE TREATMENT OF EGG CANCER |
| RU2734900C1 (ru) | 2017-03-31 | 2020-10-26 | Фуджифилм Корпорэйшн | Липосомальная композиция и фармацевтическая композиция |
| PL3811931T3 (pl) | 2018-06-20 | 2024-11-18 | Fujifilm Corporation | Skojarzony środek leczniczy zawierający kompozycję liposomową z kapsułkowanym lekiem i inhibitor punktu kontroli immunologicznej |
| TWI837189B (zh) | 2018-10-01 | 2024-04-01 | 日商富士軟片股份有限公司 | 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥 |
| JPWO2022250013A1 (https=) * | 2021-05-24 | 2022-12-01 |
-
2023
- 2023-11-21 TW TW112144902A patent/TW202434243A/zh unknown
- 2023-11-21 WO PCT/JP2023/041699 patent/WO2024111564A1/ja not_active Ceased
- 2023-11-21 JP JP2024560151A patent/JPWO2024111564A1/ja active Pending
- 2023-11-21 CN CN202380079383.3A patent/CN120225196A/zh active Pending
- 2023-11-21 EP EP23894569.5A patent/EP4623915A4/en active Pending
-
2025
- 2025-05-12 US US19/204,761 patent/US20250268827A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202434243A (zh) | 2024-09-01 |
| EP4623915A4 (en) | 2026-04-01 |
| WO2024111564A1 (ja) | 2024-05-30 |
| CN120225196A (zh) | 2025-06-27 |
| EP4623915A1 (en) | 2025-10-01 |
| US20250268827A1 (en) | 2025-08-28 |